MDL Track
MDL 3029
D. Mass.
Covidien/Parietex hernia mesh
2,348 pending
Medical Device · claims involving Covidien and Parietex hernia mesh failures, adhesion, migration, and revision surgery
Defendant
Covidien LP
MDL / Track
MDL 3029
D. Mass.
Judge
Judge Patti B. Saris
Plaintiffs
roughly 2,357 pending claims (2,348 per JPML's March 2, 2026 report, plus ~9 new filings tracked since)
Bellwether / Trial
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
On August 4, 2026, a federal jury in Boston returned an $88 million compensatory verdict against Covidien in Patterson v. Covidien Inc., No. 1:22-cv-10153, the first bellwether trial from MDL No. 3029 (In re: Covidien Hernia Mesh Products Liability Litigation) before U.S. District Judge Patti B. Saris. The jury awarded $77 million to Larry Patterson and $11 million to his wife Tammy for loss of consortium, finding Covidien negligently failed to warn physicians about dangers of its Symbotex Composite mesh, though it declined punitive damages and found Covidien "by mistake and innocently" made false statements rather than acting intentionally or recklessly. Medtronic has indicated it will pursue post-trial motions and appeal. The MDL now comprises more than 2,500 cases alleging defective design and inadequate labeling of Covidien hernia mesh products including Parietex, ProGrip, and Symbotex.
Causation Theory
Plaintiffs allege Covidien's Symbotex Composite mesh employs a porcine-derived collagen barrier that resorbs in approximately seven days—far faster than the roughly 30-day window represented to surgeons—leaving the underlying polyester mesh exposed to bowel tissue during the critical 7-10 day peritoneal healing period. Covidien's own chief scientist testified the collagen coating was not "functional" after seven days and could absorb within hours. The exposed polyester triggers a heightened foreign body inflammatory response, causing adhesions that progress to bowel obstruction, fistula, infection, and mesh fragmentation requiring surgical resection. Preclinical studies showed Symbotex's collagen film was "markedly to severely degraded" at four weeks, with adhesion rates comparable to predicate devices, yet plaintiffs contend Covidien concealed the accelerated resorption kinetics from implanting physicians.
Case Management Orders
Litigation status
MDL 3029 is in active bellwether phase before Judge Patti B. Saris in D. Mass. following an $88 million plaintiff verdict in Patterson v. Covidien, No. 1:22-cv-10153, the first federal bellwether trial. Judge Saris set a January 2027 trial date for the second bellwether per September 2026 scheduling events; post-trial motions in Patterson remain pending.
MDL Track
MDL 3029
D. Mass.
Covidien/Parietex hernia mesh
2,348 pending
State Court Activity
thousands of additional claims pending in Massachusetts and Minnesota state courts per press reports
MDL 3029 Leadership
Plaintiff Leadership
Plaintiffs' Lead Counsel
Plaintiff
Defense Leadership
Defense National Counsel
Jessica Wilson
DLA Piper
Geographic exposure
MDL 3029 (In re: Covidien Hernia Mesh Products Liability Litigation No. II) consolidated 900 cases January 2024; now exceeds 2,500 cases nationwide. Products: Parietex, ProGrip, Symbotex. Core allegations: polyester mesh causes inflammation, heightened foreign body response, fatigue fracture, fragmentation; collagen barrier dissolves faster than represented (Patterson: ~7 days vs. 30-day physician expectation). August 2026 bellwether verdict largest compensatory award in 15-year U.S. mesh litigation history.
MDL 3029 hub. U.S. District Court for the District of Massachusetts, Judge Patti B. Saris presiding. 2,453 actions pending as of Sept. 1, 2026 per MDL statistics. First federal bellwether trial (Patterson v. Covidien, No. 1:22-cv-10153) resulted in $88 million verdict August 4, 2026. Covidien headquartered in Mansfield, Massachusetts.
Plaintiff Larry Patterson implanted with Symbotex mesh in 2017 during incisional hernia repair. Bellwether verdict of $77 million compensatory to Patterson, $11 million loss of consortium to spouse. Case tried under Alabama law including Alabama Extended Manufacturer's Liability Doctrine.
Pensacola-based Levin Papantonio law firm holds plaintiffs' leadership role in MDL 3029. Shareholder Timothy M. O'Brien serves on Plaintiffs' Executive Committee and led Patterson bellwether trial team.
Prior Covidien/Parietex litigation: Avendt v. Covidien Inc., 262 F.Supp.3d 493 (E.D. Mich. 2017). Plaintiff Robert Avendt received Parietex synthetic mesh August 2008; mesh folded, required explant with bowel dissection. Court granted summary judgment for Covidien on Permacol biologic mesh claims.
Key defendants
Covidien LP
Role: Manufacturer
Headquartered in District of Massachusetts; centralization hub for MDL 3029. Facing ~900 federal suits plus Massachusetts state coordination. Ordered Feb. 2024 to produce unredacted complaint files. Bellwether trials scheduled 2025-2026.
Medtronic, Inc.
Role: Parent/Related Corporate Defendant
Named in MDL 3029 transfer order alongside Covidien entities. Corporate disclosure identifies MEDTRONIC plc as parent. Defense posture coordinated with Covidien LP through unified appearance filings.
Sofradim Productions SAS
Role: Manufacturer/Supplier
French entity named in MDL 3029; produces Parietex mesh components. Transferred into D. Mass. with Covidien defendants. Limited separate docket activity; indemnity posture unclear.
| Defendant | Role | Intelligence Note |
|---|---|---|
| Covidien LP | Manufacturer | Headquartered in District of Massachusetts; centralization hub for MDL 3029. Facing ~900 federal suits plus Massachusetts state coordination. Ordered Feb. 2024 to produce unredacted complaint files. Bellwether trials scheduled 2025-2026. |
| Medtronic, Inc. | Parent/Related Corporate Defendant | Named in MDL 3029 transfer order alongside Covidien entities. Corporate disclosure identifies MEDTRONIC plc as parent. Defense posture coordinated with Covidien LP through unified appearance filings. |
| Sofradim Productions SAS | Manufacturer/Supplier | French entity named in MDL 3029; produces Parietex mesh components. Transferred into D. Mass. with Covidien defendants. Limited separate docket activity; indemnity posture unclear. |
Timeline
MDL 3029 Formed in Massachusetts
The Judicial Panel on Multidistrict Litigation consolidated federal Covidien hernia mesh cases before U.S. District Judge Patti B. Saris in the District of Massachusetts. In re: Covidien Hernia Mesh Products Liability Litigation No. II, MDL No. 1:22-md-03029.
JPML Expands MDL to 900 Cases
The Judicial Panel on Multidistrict Litigation consolidated approximately 900 cases in MDL 3029 before the U.S. District Court for the District of Massachusetts. The docket later grew to more than 2,500 cases.
Coordinated Discovery Completed
Parties in MDL 3029 completed coordinated discovery and prepared representative bellwether cases for trial.
First Bellwether Trial Scheduled
U.S. District Judge Patti B. Saris scheduled Patterson v. Covidien Inc., No. 1:22-cv-10153, as the first federal bellwether trial in MDL 3029. Court-ordered mediation ended without global resolution earlier in 2026.
Patterson Bellwether Trial Begins
The first federal bellwether trial began in Massachusetts. Plaintiffs presented evidence that Symbotex Composite mesh's porcine collagen barrier resorbed in approximately seven days rather than the represented 30 days, causing bowel adhesion. Patterson v. Covidien Inc., No. 1:22-cv-10153 (D. Mass.).
$88 Million Verdict for Pattersons
A federal jury in Boston returned an $88 million compensatory verdict against Covidien: $77 million to Larry Patterson and $11 million to Tammy Patterson for loss of consortium. The jury found failure to warn physicians but declined punitive damages and rejected intentional misrepresentation. Largest reported compensatory award in U.S. mesh products litigation. Patterson v. Covidien Inc., No. 1:22-cv-10153, member case in MDL 3029 (D. Mass.).
Medtronic Announces Appeal
Medtronic stated it disagrees with the Patterson verdict and will pursue post-trial motions and appeal. No second bellwether trial date had been publicly scheduled as of mid-August 2026. Approximately 2,449 actions remained pending per the August 1, 2026 JPML report.
Statute of limitations
MDL 3029 (In re: Covidien Hernia Mesh Products Liability Litigation) before Judge Patti B. Saris in D. Mass. does not toll state SOLs. First bellwether trial scheduled July 2026; mediation deadline January 14, 2026. No federal preemption applies to state-law failure-to-warn and design defect claims. Cross-jurisdictional screening requires careful accrual analysis for plaintiffs with revision surgeries in multiple states.
Massachusetts
3 years from discovery
Rule: Mass. Gen. Laws ch. 260, § 2A; discovery rule applies per common law
Discovery: Accrues when plaintiff knew or should have known of injury and its causal link to product
MDL 3029 centralized in D. Mass. before Judge Patti B. Saris. First bellwether trial reset for July 2026. Mediation deadline extended to January 14, 2026. No tolling effect from MDL consolidation—state SOL controls.
California
2 years from discovery
Rule: Cal. Code Civ. Proc. § 335.1; discovery rule codified at § 338
Discovery: Accrues when plaintiff discovers or should have discovered injury and probable cause
Large plaintiff pool. No pending revival statute.
Florida
4 years from discovery
Rule: Fla. Stat. § 95.11(3)(a); discovery rule applies per Tischner v. DH Griffin Wrecking Co., 947 So. 2d 1223 (Fla. 2006)
Discovery: Accrues when plaintiff knew or should have known of injury and defendant's potential liability
Substantial Covidien filings. No current revival window.
New York
3 years from discovery
Rule: N.Y. C.P.L.R. § 214(2); discovery rule applies per LaBarbera v. Morgan, 814 N.Y.S.2d 535 (App. Div. 2006)
Discovery: Accrues when plaintiff discovers or should have discovered injury and its cause
Large volume jurisdiction. No revival legislation pending.
Texas
2 years from discovery
Rule: Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule applies per S.V. v. R.V., 933 S.W.2d 1 (Tex. 1996)
Discovery: Accrues when plaintiff knew or should have known of injury and its cause in fact
Significant plaintiff base. No tolling from MDL 3029.
Pennsylvania
2 years from discovery
Rule: 42 Pa. Cons. Stat. § 5524(2); discovery rule applies per Pocono Int'l Raceway, Inc. v. Pocono Produce, Inc., 468 A.2d 468 (Pa. 1983)
Discovery: Accrues when plaintiff knows or reasonably should know of injury and its cause
Active filing state. No pending revival.
Rhode Island
3 years from discovery of wrongdoing
Rule: R.I. Gen. Laws § 9-1-14(b); extended rule per Anthony v. Abbott Labs., 490 A.2d 43 (R.I. 1985)
Discovery: Accrues when plaintiff discovers or should discover manufacturer's wrongdoing—not merely injury
Anthony rule provides extended accrual theory distinct from standard discovery rule. Applies to product liability generally, not Bard-specific. Forum non conveniens risk for non-residents.
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| Massachusetts | 3 years from discovery | Mass. Gen. Laws ch. 260, § 2A; discovery rule applies per common law | Accrues when plaintiff knew or should have known of injury and its causal link to product | MDL 3029 centralized in D. Mass. before Judge Patti B. Saris. First bellwether trial reset for July 2026. Mediation deadline extended to January 14, 2026. No tolling effect from MDL consolidation—state SOL controls. |
| California | 2 years from discovery | Cal. Code Civ. Proc. § 335.1; discovery rule codified at § 338 | Accrues when plaintiff discovers or should have discovered injury and probable cause | Large plaintiff pool. No pending revival statute. |
| Florida | 4 years from discovery | Fla. Stat. § 95.11(3)(a); discovery rule applies per Tischner v. DH Griffin Wrecking Co., 947 So. 2d 1223 (Fla. 2006) | Accrues when plaintiff knew or should have known of injury and defendant's potential liability | Substantial Covidien filings. No current revival window. |
| New York | 3 years from discovery | N.Y. C.P.L.R. § 214(2); discovery rule applies per LaBarbera v. Morgan, 814 N.Y.S.2d 535 (App. Div. 2006) | Accrues when plaintiff discovers or should have discovered injury and its cause | Large volume jurisdiction. No revival legislation pending. |
| Texas | 2 years from discovery | Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule applies per S.V. v. R.V., 933 S.W.2d 1 (Tex. 1996) | Accrues when plaintiff knew or should have known of injury and its cause in fact | Significant plaintiff base. No tolling from MDL 3029. |
| Pennsylvania | 2 years from discovery | 42 Pa. Cons. Stat. § 5524(2); discovery rule applies per Pocono Int'l Raceway, Inc. v. Pocono Produce, Inc., 468 A.2d 468 (Pa. 1983) | Accrues when plaintiff knows or reasonably should know of injury and its cause | Active filing state. No pending revival. |
| Rhode Island | 3 years from discovery of wrongdoing | R.I. Gen. Laws § 9-1-14(b); extended rule per Anthony v. Abbott Labs., 490 A.2d 43 (R.I. 1985) | Accrues when plaintiff discovers or should discover manufacturer's wrongdoing—not merely injury | Anthony rule provides extended accrual theory distinct from standard discovery rule. Applies to product liability generally, not Bard-specific. Forum non conveniens risk for non-residents. |
Live intelligence
AI litigation brief
Covidien Hernia Mesh remains established mass tort / active mdl with 66 current signals in the accepted feed.
Overview
MDL 3029 is in active bellwether phase before Judge Patti B. Saris in D. Mass. following an $88 million plaintiff verdict in Patterson v. Covidien, No. 1:22-cv-10153, the first federal bellwether trial. Judge Saris set a January 2027 trial date for the second bellwether per September 2026 scheduling events; post-trial motions in Patterson remain pending.
Key developments
Trajectory
Court filings and press coverage are both active in MDL 3029, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.
Editorial intelligence
MDL 3029 should stay on the lead docket watch because it is the primary consolidation vehicle for Covidien Hernia Mesh.
Generated Sep 30, 2026, 9:00 AM UTC
66 events detected
Google News (30)
Covidien MDL Judge Sets January 2027 Date For 2nd Bellwether Trial - mealeys.com
Covidien MDL Judge Sets January 2027 Trial Date For 2nd Bellwether Trial - Mealey's
Lawyers set high bar with $88M verdict in hernia mesh MDL - Massachusetts Lawyers Weekly
Hernia Mesh Lawsuit: Payouts & Deadlines (Aug 2026) - LawFold.com
Covidien Hernia Verdict Trimming Likely, Federal Judge Signals in Massachusetts - USA Herald
Judge May Trim $88M Covidien Hernia Mesh Verdict - Law360
$88 Million Verdict in First Federal Covidien Hernia Mesh Bellwether Trial - TMX Newsfile
Hernia Mesh Lawsuit Settlements (Updated August 2026) - LawFold.com
Jury Orders Medtronic to Pay $88 Million After Finding Surgeons Were Not Adequately Warned About a Hernia Mesh - medicaldaily.com
US jury says Medtronic owes $88 million in first case to go to trial over Covidien's hernia mesh - Patient Safety Learning - the hub
Medtronic Hit with $88M Verdict in Hernia Mesh Lawsuit - Medical Device and Diagnostic industry
Jury says Medtronic must pay $88M in Covidien hernia mesh suit - MassDevice
Etowah Co. couple awarded $88 million in landmark hernia mesh verdict - WBMA
1st Covidien MDL Bellwether Trial Ends With $88 Million Jury Award - Mealey's
Levin Papantonio Client Awarded $88 Million Verdict in First Federal Covidien Hernia Mesh Bellwether Trial - GlobeNewswire
Federal Jury Awards $88 Million in First Covidien Hernia Mesh Bellwether Trial - scanx.trade
Jury rules Medtronic owes $88M in first case about hernia treatment products - Red Lake Nation News
US jury says Medtronic owes $88 million in first case to go to trial over Covidien’s hernia mesh By Reuters - Investing.com
Medtronic faces $88 million verdict in hernia mesh trial - Investing.com
BREAKING: Bellwether Jury Awards $88M In Covidien Hernia Mesh Trial - law360.com
Bellwether Jury Awards $88M In Covidien Hernia Mesh Trial - law360.com
Medtronic faces $88 million verdict in hernia mesh trial By Investing.com - Investing.com Australia
Medtronic Ordered to Pay $88 Million in First Hernia Mesh Test Trial - Межа. Новини України.
US Jury Orders Medtronic to Pay $88M in Covidien Hernia Mesh Case - Global Banking & Finance Review
US jury says Medtronic owes $88 million in first case to go to trial over Covidien's hernia mesh - Reuters
An Alabama resident, who is suing Medtronic's Covidien unit over injuries he says were caused by a hernia mesh product, exits the federal courthouse in Boston - The Daily News | Texas' Oldest Newspaper
Covidien Hid Mesh Risks, Bellwether Jury Told As Trial Ends - law360.com
With 10,000 lawsuits pending, Medtronic’s hernia mesh faces its first jury - Star Tribune
Medtronic faces first trial in US hernia mesh injury cases - Reuters
Covidien Hid Mesh Risk From Doctors, Bellwether Jury Told - Law360
No recent PubMed signals. Monitoring is active — this section updates automatically.
Covidien Hernia Mesh Products Liability Litigation (No. II)
PACER docket filed in JPML: The plaintiffs claim that Covidien LP and Sofradim Production SAS produced and sold defective hernia mesh devices, leading to injuries related to their defective nature. The involved products include Dextile Anatomical Mesh, Parietene DS Mesh, Parietene Polypropylene Mesh, among others. The lawsuit
Plaintiff Fact Sheet Instructions
Order requiring plaintiffs to complete and submit a Plaintiff Fact Sheet (PFS) for each individual plaintiff in the MDL, with definitions and instructions.
Protective Order
The court adopts the stipulated protective order with modifications, governing the use and designation of confidential discovery materials in the MDL.
Covidien Hernia Mesh Products Liability Litigation (No. II)
PACER docket entry from MAD: COMPLAINT against Sofradim Production SAS, Covidien LP Filing fee: $ 405, receipt number AMADC-12074275 (Fee Status: Filing Fee paid), filed by Alexander Nero. (Attachments: # 1 Civil Cover Sheet, # 2 Category Form)(Vaughn, C. Brett) (Entered: 09/29/2026)
Plaintiff Fact Sheet Instructions
Order requiring plaintiffs to complete and submit a Plaintiff Fact Sheet (PFS) for each individual plaintiff in the MDL, with definitions and instructions.
Protective Order
The court adopts the stipulated protective order with modifications, governing the use and designation of confidential discovery materials in the MDL.
Covidien Hernia Mesh Products Liability Litigation (No. II)
PACER docket entry from MAD: COMPLAINT against Sofradim Production SAS, Covidien LP Filing fee: $ 405, receipt number AMADC-12043713 (Fee Status: Filing Fee paid), filed by Charles Vandenburg. (Attachments: # 1 Civil Cover Sheet)(Fantini, Joseph) Modified on 9/18/2026: Removed duplicate text. (FGD) (Entered: 09/18/2026)
Covidien Hernia Mesh Products Liability Litigation (No. II)
PACER docket entry from MAD: COMPLAINT against All Defendants Filing fee: $ 405, receipt number AMADC-12033716 (Fee Status: Filing Fee paid), filed by Candida Slechta. (Attachments: # 1 Civil Cover Sheet)(Hollingsworth, Caroline) (Entered: 09/15/2026)
Covidien Hernia Mesh Products Liability Litigation (No. II)
PACER docket entry from MAD: COMPLAINT against Sofradim Production SAS, Covidien LP Filing fee: $ 405, receipt number AMADC-12027486 (Fee Status: Filing Fee paid), filed by Frank Fernandez, Jr. (Attachments: # 1 Civil Cover Sheet, # 2 Category Form)(Vaughn, C. Brett) (Entered: 09/11/2026)
Covidien Hernia Mesh Products Liability Litigation (No. II)
PACER docket entry from MAD: COMPLAINT against Sofradim Production SAS, Covidien LP Filing fee: $ 405, receipt number AMADC-12012204 (Fee Status: Filing Fee paid), filed by Jonathan Cates. (Attachments: # 1 Civil Cover Sheet)(Fantini, Joseph) Modified on 9/8/2026 Removing duplicate text(CEW). (Entered: 09/05/2026)
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
88Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Sep 30, 2026, 9:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
MAUDE
PubMed
Event feed
66
events detected
AI Brief
Covidien Hernia Mesh remains established mass tort / active mdl with 66 current signals in the accepted feed.
Overview
MDL 3029 is in active bellwether phase before Judge Patti B. Saris in D. Mass. following an $88 million plaintiff verdict in Patterson v. Covidien, No. 1:22-cv-10153, the first federal bellwether trial. Judge Saris set a January 2027 trial date for the second bellwether per September 2026 scheduling events; post-trial motions in Patterson remain pending.
Key developments
PACER court filing on Dec 31: Covidien Hernia Mesh Products Liability Litigation (No. II). ‖ mealeys.com news on Sep 15: Covidien MDL Judge Sets January 2027 Date For 2nd Bellwether Trial - mealeys.com. ‖ MAUDE FDA alert on Aug 28: MAUDE Filing 50502989: Progrip.
Generated Sep 30, 2026, 9:00 AM UTC
Tracked MDLs
MDL 3029
D. Mass.
Covidien/Parietex hernia mesh